CTLA4 and colorectal carcinoma: SL-CRC shows higher treatment responses under CTLA4 (−)/PD-1 (−) and CTLA4 (+)/PD-1 (−) conditions, potentially due to fewer immunosuppressive factors or different immune regulatory mechanisms, allowing immune checkpoint inhibitors to more effectively “unleash” immune cells (Wang et al., 2021).